bioRxivImmunology
Heterologous Prime-Boost with Immunologically Orthogonal Protein Nanoparticles for Peptide Immunofocusing
S. Bhattacharya, M. C. Jenkins, P. Keshavarz-Joud, A. R. Bourque, K. White, A. M. A. Barkane, A. V. Bryksin, C. Hernandez, M. Kopylov, M. G. Finn
Abstract
Protein nanoparticles are effective platforms for antigen presentation and targeting effector immune cells in vaccine development. Encapsulins are a class of protein-based microbial nanocompartments that self-assemble into icosahedral structures with external diameters ranging from 24 to 42 nm. Encapsulins from Mxyococcus xanthus were designed to package bacterial RNA when produced in E. coli and were shown to have immunogenic and self-adjuvanting properties enhanced by this RNA. We genetically incorporated a 20-mer peptide derived from a mutant strain of the SARS-CoV-2 receptor binding domain (RBD) into the encapsulin protomeric coat protein for presentation on the exterior surface of the particle. This immunogen elicited conformationally-relevant humoral responses to the SARS-CoV-2 RBD. Immunological recognition was enhanced when the same peptide was presented in a heterologous prime/boost vaccination strategy using the engineered encapsulin and a previously reported variant of the PP7 virus-like particle, leading to the development of a selective antibody response against a SARS-CoV-2 RBD point mutant. While generating epitope-focused antibody responses is an interplay between inherent vaccine properties and B/T cells, here we demonstrate the use of orthogonal nanoparticles to fine-tune the control of epitope focusing. Table of Contents graphic O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=121 SRC="FIGDIR/small/581861v1_ufig1.gif" ALT="Figure 1"> View larger version (21K): org.highwire.dtl.DTLVardef@53407corg.highwire.dtl.DTLVardef@1ae8d0eorg.highwire.dtl.DTLVardef@aec021org.highwire.dtl.DTLVardef@c7e0ef_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: human
- organism: E. coli
- organism: mouse
- assay: protein structure
- assay: proteomics
- research focus: host-pathogen & immune response
- research focus: cell type annotation
- research focus: drug response / drug discovery
- research focus: protein design
- approach: experimental assay
- approach: genetic perturbation / CRISPR
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2
A. C. Walls, B. Fiala, … N. P. King·bioRxiv·Aug 11, 2020
- Computationally designed mRNA-launched protein nanoparticle vaccines
Grace G. Hendricks, Lilit Grigoryan, … Neil P. King·Science Translational MedicinePeer-reviewed·Oct 15, 2025
- Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates
- A single extracellular vesicle-based platform supporting both RBD protein and mRNA vaccination against SARS-CoV-2
Jihwa Chung, Kyoung Hwa Kim, … Seok-Hyun Kim·Journal of Controlled ReleasePeer-reviewed·Dec 6, 2025
- DNA Origami Presenting the Receptor Binding Domain of SARS-CoV-2 Elicit Robust Protective Immune Response
E. Oktay, F. Alem, … R. Veneziano·bioRxiv·Aug 2, 2022
- Rationally designed multimeric nanovaccines using icosahedral DNA origami for molecularly controlled display of SARS-CoV-2 receptor binding domain